PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

NCT ID: NCT05954286

Last Updated: 2025-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-29
• Study Completion Date: 2025-04-24

Brief Summary

This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Detailed Description

This multicenter trial will be conducted in both domestic and international sites. The study will compare IPs to control in standard and intermediate risk, non-hospitalized adult SARS-CoV-2 infected participants and uninfected adult contacts of SARS-CoV-2 confirmed cases. The master protocol will outline the core elements of the study. Investigational products may be included in either or both study indications: early treatment and post-exposure prophylaxis (PEP). The study includes a phase 2 evaluation for all IPs. The platform trial design will allow for multiple IPs to be incorporated into the protocol as product specific appendices (PSA) as products are identified and become available. Each PSA will detail the interventions, the endpoints, target treatment effect, intended statistical analysis, the relevant control arms, and the sample size range. The PSA may define additional adaptive design elements, such as early declaration rules.

Conditions

SARS-CoV-2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Early Treatment: Upamostat 400 mg

400 mg (2 x 200 mg) capsules administered orally once daily for 14 days

Group Type: EXPERIMENTAL

Upamostat

Intervention Type: DRUG

Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.

Early Treatment: Placebo Oral Capsule

The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way.

Group Type: PLACEBO_COMPARATOR

Placebo (PO)

Intervention Type: DRUG

Oral Capsules

Interventions

Upamostat

Upamostat is available as a hydrogen sulphate salt (also designated as WX-671.1). WX-671.1 is a white to yellowish powder which is freely soluble in dimethyl sulfoxide and soluble in ethanol. The drug substance is very slightly soluble in water or 0.1 M HCl.

Intervention Type: DRUG

Placebo (PO)

Oral Capsules

Intervention Type: DRUG

Other Intervention Names

WX-671; RHB-107

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years

2. Positive molecular or antigen diagnostic test for SARS-CoV-2 at study enrollment or within ≤ 5 days prior to enrollment

3. Presence of two or more Screening Symptoms listed in Supplement 3 with at least two symptoms classified as moderate to severe (and/or ≥ 2 on the frequency questions or loss of taste/smell questions) at the time of enrollment a. For participants who have preexisting conditions causing mild or moderate symptoms listed on the Screening Symptom Questionnaire, there must be an increase of at least one severity level for that symptom at enrollment (For example, prior to illness participant routinely experienced headaches rated as moderate severity, now rating headache as severe at enrollment)

• Supplement 3 Screening Symptoms: stuffy or runny nose, hoarse voice, sore throat, difficulty breathing, cough, fatigue (low energy or tiredness), muscle or body aches, headache, fever (documented temperature > 38° C [100.4° F]) or subjective fever, chills or shivering, feeling hot or feverish, nausea, vomiting, diarrhea, loss of smell, loss of taste

4. Symptom onset ≤ 5 days prior to enrollment

1. Age ≥ 18 years

2. Asymptomatic contact of an individual with laboratory confirmed SARS-CoV-2 infection defined as:

a. Indoor exposure to the symptomatic case or cases within 6 feet (2 meters) for ≥ 15 minutes over a 24-hour period without the use of personal protective equipment

3. Negative screening SARS-CoV-2 molecular or antigen diagnostic test performed at screening or within less than or equal to 24 hours of enrollment

4. Exposure and enrollment within 6 days or less from when the symptomatic, confirmed SARS-CoV-2 positive case first had symptoms

1. Women of childbearing potential must agree to use an effective contraceptive method upon enrollment in the study through 8 weeks after the last dose of the investigational product. This would include oral contraceptives, implanted contraceptives, intrauterine devices, and barrier methods.

• A woman is considered of childbearing potential unless post-menopausal (subject is at least 50 years old and has a history of ≥ 2 years without menses without other known or suspected cause), or permanently surgically sterilized.
• Participants not of reproductive potential are eligible without requiring the use of a contraceptive method. Participant-reported history is acceptable documentation of surgical sterilization and menopause.

Exclusion Criteria

1. Hospital admission at the time of enrollment

2. Hospitalization will be defined as requiring medical care not available in an outpatient setting for greater than 24 hours

3. Hospitalization for isolation or quarantine requirements or for social reasons will NOT constitute an exclusion criterion

4. Laboratory confirmed SARS-CoV-2 infection 6 to 90 days prior to enrollment

5. Oxygen saturation < 92% on room air

6. Baseline use of supplemental oxygen at the time of enrollment

7. Presence of any of the following comorbidities that per the PI puts the patient at high risk of developing severe COVID-19 illness:

a. Age ≥ 75 years b. Active treatment for solid tumor and hematologic malignancies c. Hematologic malignancy, myeloma, or related disorder (e.g., myelodysplastic syndrome, myelofibrosis) d. Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy e. Chemotherapy or radiotherapy for solid organ cancer in the last 12 months f. Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) g. Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) h. Advanced or untreated HIV infection (people with HIV and CD4 cell counts less than 200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) i. Active treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory j. Sickle cell disease k. Chronic liver disease (e.g., Child-Pugh Class A, B or C cirrhosis) l. Down syndrome m. Dementia or neurocognitive disability (e.g., Parkinson's disease) n. Participants with 3 or more of the following conditions: i) No prior COVID-19 infection OR has not completed a COVID-19 vaccine series within the last 6 months OR has not received a vaccine booster within the last 6 months ii) Age 65-74 years iii) BMI ≥35 (or >95th percentile in adolescents) iv) Type 1 or type 2 diabetes mellitus v) Cardiovascular disease (including HTN if age >55) vi) Chronic lung disease (including bronchiectasis, CF, COPD, ILD, PHTN, PE, moderate-to-severe asthma) vii) Chronic kidney disease (eGFR <30)

8. Participants who are receiving or plan to receive anti-SARS-CoV-2 antivirals for treatment of their COVID-19

Population B: Uninfected adult contacts of symptomatic SARS-CoV-2 infected individuals

1. Symptoms attributed to COVID-19 as assessed by the investigator 2. Positive molecular or antigen diagnostic test for SARS-CoV-2 from any upper respiratory specimen within 90 days prior to enrollment 3. SARS-CoV-2 vaccination within 90 days prior to enrollment EXCEPT if severely immunocompromised or a known vaccine non-responder 4. Severely immunocompromised or a known vaccine non-responder defined as: solid organ or stem cell transplant recipient, B cell leukemia, receiving B cell depletion therapy (e.g., rituximab), agammaglobulinemia, or negative serology ≥2 weeks after vaccination with two doses of a vaccine 5. Hospital admission at the time of enrollment

1. Hospitalization will be defined as requiring medical care not available in an outpatient setting for greater than 24 hours 6. Hospitalization for isolation or quarantine requirements or for social reasons will NOT constitute an exclusion criterion

For Both populations:

1. Absence of informed consent

2. Pregnancy

3. Breastfeeding

4. Individuals who the study investigators believe are unable to comply with the requirements of the study

5. Participation in another intervention trial for the treatment or prophylaxis of SARS-CoV-2 infection or COVID-19 disease at the time of enrollment

Additional Criteria for the Early Treatment Upamostat Arm:

1. Patient is currently taking or is expected to start taking warfarin, apixaban (Eliquis), or rivaroxaban (Xarelto). Patients may be taking or start on study dabigatran (Pradaxa), standard or low molecular weight heparin.

2. Patients with prolonged QT/QTc interval and/or increased susceptibility to arrythmia defined as the presence of any of the following:

• QTc interval > 450 msec

• Pathological Q-waves (defined as Q-wave > 40 msec or depth > 0.4-0.5 mV)

• Evidence of ventricular pre-excitation

• Electrocardiographic evidence of complete LBBB, RBBB, incomplete LBBB, in complete RBBB

• Evidence of second- or third-degree heart block
• Intraventricular conduction delay with QRS duration > 120 msec
• Bradycardia as defined by sinus rate< 50 bpm
• Personal or family history of long QT syndrome
• Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, except for sinus arrhythmia
• Syncopal episodes or additional risk factors for torsades de points (e.g., heart failure, hypokalemia)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies

OTHER_GOV

Sponsor Role: collaborator

RedHill Biopharma Limited

INDUSTRY

Sponsor Role: collaborator

FHI Clinical, Inc.

UNKNOWN

Sponsor Role: collaborator

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Johns Hopkins Hospital

Baltimore, Maryland, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

KUR Research

Nashville, Tennessee, United States

Josha Research

Bloemfontein, , South Africa

Royal Thai Army Clinical Research Center (RTA CRC) Royal Thai Army-Armed Forces Research Institute of Medical Sciences (RTA-AFRIMS)

Bangkok, , Thailand

Makerere University Walter Reed Project

Fort Portal, , Uganda

Countries

United States; South Africa; Thailand; Uganda

Other Identifiers

PC06

Identifier Type: -

Identifier Source: org_study_id